AstraZeneca's Opioid Drug Trial Setback: A Significant Challenge for Addiction Treatments
Click to start listening
New Delhi, Nov 27 (NationPress) The unsuccessful trial of the drug AZD4041 by pharmaceutical leader AstraZeneca in addressing opioid use disorder (OUD) reveals the complexities involved in developing non-opioid solutions for addiction and withdrawal, according to a report published on Wednesday.
OUD is recognized as a chronic neurological condition that results in the compulsive and repeated consumption of opioid substances, leading to extended self-administration.
The company has recently halted the progress of AZD4041 during its Phase II trial, as the orexin 1 receptor antagonist exhibited a drug-drug interaction with an antifungal medication.
The analysis from GlobalData, a data and analytics organization, indicated that six out of the seven agents currently undergoing late-stage development (Phases IIb–III) are non-opioids. It also emphasized a notable deficiency in efficacy data for the other agents in the pipeline.
“Opioid agonists are prevalent in the treatment sphere for OUD, but their application is accompanied by the risk of 'diversion' -- the unauthorized use of opioid medications -- which often necessitates that their distribution be confined to specialized treatment programs,” explained Jos Opdenakker, Pharma Analyst at GlobalData.
Opdenakker noted that these challenges have propelled significant efforts to innovate non-opioid drugs for treating addiction and withdrawal.
Faced with strong competition from existing opioid treatments, “locating a non-opioid alternative that can rival their efficacy is presenting considerable difficulties,” he remarked.
Moreover, the report indicated that non-opioid treatments in development are anticipated to emerge in the market as adjunctive therapies alongside the current first-line options. Thus, they are unlikely to replace standard opioid treatments -- like methadone or buprenorphine -- as primary solutions for OUD, the report stated.
The report also predicts that opioid agonist therapies could generate combined sales nearing $1.75 billion by 2033 across eight major markets -- the US, France, Germany, Italy, Spain, UK, Canada, and Australia -- accounting for 83.8 percent of the OUD market.
This market prevalence highlights the absence of effective alternatives to opioid agonist therapies, as well as the significant influence of patient preferences in the treatment of OUD.
“The treatment landscape for OUD is lacking an effective non-opioid therapy capable of competing with the current opioid agonists. While opioid agonists remain the gold standard for treating OUD, they have not resolved the ongoing opioid crisis,” Opdenakker stated.
“Any non-opioid treatment that successfully reaches the market with strong efficacy and safety standards for OUD is likely to experience substantial adoption and could potentially disrupt the OUD market,” he concluded.
